Iron isomaltoside 1000

Drug Profile

Iron isomaltoside 1000

Alternative Names: Iron oligosaccharide; Isofer; Jilazo; Monofar; Monofer

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Pharmacosmos
  • Developer Cosmopharm; Pharmacosmos
  • Class Antianaemics; Disaccharides; Ferric compounds
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Iron deficiency anaemia
  • Phase III Metabolic disorders

Most Recent Events

  • 05 Jan 2017 Pharmacosmos plans a phase I trial for Iron deficiency anaemia in Japan (IV, Injection and IV, Infusion) (NCT03013439)
  • 19 Dec 2016 Pharmacosmos and Nippon Shinyaku agree to co-promote and co-develop Iron isomaltoside 1000 in Japan for Iron deficiency
  • 17 Nov 2016 Launched for Iron deficiency anaemia in India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top